Investor Overview

Stock Information
Loading data...

Shares outstanding

10,730,210 (as of 11/9/2023)

Press Releases
Feb 1, 2024

Evofem Delivers Third Consecutive Year of Phexxi Net Sales Growth Total Operating Expense Reduced More Than 60% from 2022 Levels SAN DIEGO, Feb. 1, 2024 /PRNewswire/ -- Evofem Biosciences, Inc....

Jan 8, 2024

— Removal of Prior Authorization Upgrades Phexxi Coverage for Nearly 1.8 Million Washington Lives Across All Medicaid Plans — — Fans Encouraged to Plan for Victory, Prevent Unintended...

Dec 12, 2023

Evofem posted $13.4 million in net sales of Phexxi for the first nine months of 2023; Aditxt looks to accelerate Evofem into the global non-hormonal birth control market valued at $27.7 billion in...

Nov 14, 2023

— On track to achieve third consecutive year of revenue growth – — Third consecutive quarter of favorable sales and marketing expense as a percentage of net sales — — Reduced loss from...

Oct 24, 2023

— On track to achieve third consecutive year of net product sales growth — — Third consecutive quarter of favorable net product sales- to- sales and marketing expense ratio — — Reduced...

View all

Evofem Investor Presentation
Subscribe for Alerts

Company Overview

Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company committed to commercializing innovative products to address unmet needs in women's sexual and reproductive health. 

The Company‘s first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at  

The U.S. contraceptive market was estimated at $8.3 billion as of 2022. Every 1% market share of the 43.3 million women in our addressable market represents more than $300 million in net product sales for Evofem.

Evofem intends to expand Phexxi’s global reach and further increase its commercial potential through ex-U.S. licenses. The product is approved in Nigeria, and regulatory dossiers have been submitted in Ghana, Ethiopia and Mexico.

Effective October 3, 2022, the Company's common stock trades on the OTCQB Venture Market under the ticker symbol "EVFM". From May 18, 2023, until June 20, 2023, it traded under the ticker symbol "EVFMD," then reverted to the ticker symbol "EVFM".

Featured Event
Wednesday, February 28, 2024 - Saturday, March 2, 2024

Evofem is pleased to participate in the Annual Meeting of the Council on Resident Education in Obstetrics and Gynecology (CREOG), of the American College of Obstetricians and Gynecologists (ACOG)...

View All

Latest Financial Results

Q3 2023, Ended September 30, 2023

Earnings Release
10-Q Filing